Theravance Biopharma Analyst Price Targets - Benzinga

Theravance Biopharma Inc

TBPHNASDAQ

Trade with Public

Trade with Public

$17.08

Last update: Sep 4, 4:00 PM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Theravance Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Theravance Biopharma (TBPH).

Price Target Range — 9 Quarters

Analyst Consensus — 6 Analysts

6Hold

Consensus RatingNeutral# Analysts6Avg. Consensus PT$15Upside to Avg. PT-13.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Jul 7, 2026	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$15→$17
Jun 29, 2026	Jones Trading	Debanjana Chatterjee	Downgrade	Buy→Hold	—
Jun 29, 2026	BTIG	Julian Harrison	Downgrade	Buy→Neutral	—
Apr 7, 2026	B. Riley Securities	Mayank Mamtani	PT Raise	Neutral	$14→$17
Mar 23, 2026	TD Cowen	Marc Frahm	PT Raise	Hold	$13→$15
Mar 20, 2026	BTIG	Julian Harrison	Maintained	Buy	$21
Mar 5, 2026	Oppenheimer	Trevor Allred	Downgrade	Outperform→Perform	—
Mar 4, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Buy	$27→$15
Mar 4, 2026	B. Riley Securities	Mayank Mamtani	Downgrade	Buy→Neutral	$28→$14
Mar 3, 2026	BTIG	Julian Harrison	PT Cut	Buy	$40→$21
Mar 2, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$20→$27
Feb 3, 2026	BTIG	Julian Harrison	Maintained	Buy	$40
Dec 3, 2025	Oppenheimer	Trevor Allred	Initiate	Outperform	$27
Nov 26, 2025	BTIG	Julian Harrison	PT Raise	Buy	$25→$40
Nov 11, 2025	HC Wainwright & Co.	Douglas Tsao	PT Raise	Buy	$15→$20
Sep 12, 2025	B. Riley Securities	Mayank Mamtani	Initiate	Buy	$28
Jun 27, 2025	BTIG	Julian Harrison	PT Raise	Buy	$24→$25
Jun 17, 2025	Jones Trading	Debanjana Chatterjee	Initiate	Buy	$24
Feb 27, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$15
Feb 25, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17

HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.

Benzinga Newsdesk

PRO
Jones Trading Downgrades Theravance Biopharma to Hold

Jones Trading analyst Debanjana Chatterjee downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Hold.

Benzinga Newsdesk

PRO
BTIG Downgrades Theravance Biopharma to Neutral

BTIG analyst Julian Harrison downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Neutral on Theravance Biopharma, Raises Price Target to $17

B. Riley Securities analyst Mayank Mamtani maintains Theravance Biopharma (NASDAQ:TBPH) with a Neutral and raises the price target from $14 to $17.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Theravance Biopharma, Raises Price Target to $15

TD Cowen analyst Marc Frahm maintains Theravance Biopharma (NASDAQ:TBPH) with a Hold and raises the price target from $13 to $15.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Theravance Biopharma, Maintains $21 Price Target

BTIG analyst Julian Harrison reiterates Theravance Biopharma (NASDAQ:TBPH) with a Buy and maintains $21 price target.

Benzinga Newsdesk